Sugi Predict

Sugi Predict / Compounds / SCHEMBL180225

SCHEMBL180225

SCHEMBL180225

CCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HIF1A Q16665 10/20 0.84
▸ PGR P06401 4/20 0.84
▸ SERPINA6 P08185 2/20 0.84
▸ AR P10275 2/20 0.84
▸ CHRM1 P11229 2/20 0.84
▸ LMNA P02545 2/20 0.84
▸ SMN1; SMN2 Q16637 3/20 0.83
▸ MAPT P10636 2/20 0.82
▸ POLB P06746 1/20 0.82
▸ GAA P10253 1/20 0.82
▸ CYP3A4 P08684 2/20 0.81
▸ NFKB1 P19838 2/20 0.80
▸ PMP22 Q01453 1/20 0.80
▸ TSHR P16473 1/20 0.80
▸ NR3C1 P04150 6/20 0.75
▸ NR3C2 P08235 3/20 0.75
▸ CYP2C19 P33261 2/20 0.75
▸ HSD17B10 Q99714 2/20 0.75
▸ SHBG P04278 1/20 0.75
▸ KMT2A Q03164 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11234120 1.00 HIF1A (0.84) HIF1APGRSERPINA6ARCHRM1
SCHEMBL16018308 0.94 HIF1A (0.93) HIF1APGRSERPINA6ARCHRM1
SCHEMBL11252568 0.93 HIF1A (0.88) HIF1APGRSERPINA6ARCHRM1
SCHEMBL10575587 0.93 HIF1A (0.88) HIF1APGRSERPINA6ARCHRM1
SCHEMBL4696 0.93 HIF1A (0.88) HIF1APGRSERPINA6ARCHRM1
SCHEMBL2679655 0.93 HIF1A (0.88) HIF1APGRSERPINA6ARCHRM1
SCHEMBL10940291 0.93 HIF1A (0.84) HIF1APGRSERPINA6ARCHRM1
SCHEMBL10944869 0.93 HIF1A (0.84) HIF1APGRSERPINA6ARCHRM1
SCHEMBL11043424 0.92 HIF1A (0.80) HIF1APGRSERPINA6ARCHRM1
SCHEMBL80604 0.92 HIF1A (0.95) HIF1APGRSERPINA6ARCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170069-A1 NANOPREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD AND USE THEREOF XIANGYA HOSPITAL CENTRAL SOUTH UNIV (CN) 2025-05-29 — — US claimed
EP-4470532-A1 NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF Xiangya Hospital, Central South University (CN) 2024-12-04 — — EP claimed
CN-118662643-A Application of hormone medicine composition in preparation of medicine for treating osteoarthritis 中南大学湘雅医院 2024-09-20 — — CN claimed
CN-118234515-A Methods and therapeutic compositions for treating and preventing severe injection site reactions 腾盛博药生物科技有限公司 2024-06-21 — — CN claimed
CN-118122163-A Low shear mixing method for improving stability of external pharmaceutical preparation composition 江苏知原药业股份有限公司 2024-06-04 — — CN claimed
CN-116098866-A Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof 中南大学湘雅医院 2023-05-12 — — CN claimed
CN-116077669-A Glucocorticoid nano-lipid carrier for treating arthralgia, preparation method and application thereof 中南大学湘雅医院 2023-05-09 — — CN claimed
CN-113557020-A Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof 瑞真药业公司 2021-10-26 — — CN claimed
CN-113332439-A Methods of treatment and compositions comprising dual PI3K delta-gamma kinase inhibitors and corticosteroids 理森制药股份公司 2021-09-03 — — CN claimed
CN-107613985-B Aqueous suspensions of nanoparticles containing glucocorticoids 株式会社活效制药 2021-05-25 — — CN claimed
EP-1140021-B1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG (DE) 2004-08-04 — — EP claimed
US-20030232086-A1 Gel composition for the topical treatment of rashes, dermatoses and lesions MCCADDEN MICHAEL E (US) 2003-12-18 — — US claimed
US-6656928-B1 Composition for the topical treatment of rashes, dermatoses and lesions MCCADDEN MICHAEL E (US) 2003-12-02 — — US claimed
US-20030077304-A1 Gel composition for the topical treatment of poison ivy and other forms of contact dermatitis MCCADDEN MICHAEL E (US) 2003-04-24 — — US claimed
US-6479058-B1 Composition for the topical treatment of poison ivy and other forms of contact dermatitis MCCADDEN MICHAEL E (US) 2002-11-12 — — US claimed
JP-2002533379-A — — 2002-10-08 — — JP claimed
US-20020064524-A1 Formulation for topical non-invasive application in vivo IDEA AG (DE) 2002-05-30 — — US claimed
CN-1327382-A Improved formulation for topical non-invasive application in vivo IDEA INNOVAT DERMALE APPL GMBH (DE) 2001-12-19 — — CN claimed
EP-1140021-A1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG (DE) 2001-10-10 — — EP claimed
WO-2000038653-A1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG. (DE) 2000-07-06 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020064524-A1 Formulation for topical non-invasive application in vivo CUTA, LPO, GPX4 HIF1A 2297/4885PGR 3545/4885SERPINA6 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.